Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue	$ 13		$ 27	$ 5
Operating expenses:
Research and development	342	1,709	580	2,771
General and administrative	4,914	9,107	7,796	15,352
Impairment of long term assets			253
Depreciation and amortization	49	92	127	176
Total operating expenses	5,305	10,908	8,756	18,299
Loss from operations	(5,292)	(10,908)	(8,729)	(18,294)
Other income (expense):
Interest income, net	(5)	3	(8)	7
Gain on settlement and forgiveness of accounts payable	1,388		1,388
Other income (expense), net:	(2)	(225)	23	(225)
Loss before income taxes	(3,911)	(11,130)	(7,326)	(18,512)
Income taxes (benefit)
Net loss	(3,911)	(11,130)	(7,326)	(18,512)
Non-controlling interest	(4)	37	9	87
Net loss attributable to BioSig Technologies, Inc.	(3,915)	(11,093)	(7,317)	(18,425)
Preferred stock dividend	(3)	(3)	(5)	(5)
Preferred stock deemed dividend			(133)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (3,918)	$ (11,096)	$ (7,455)	$ (18,430)
Net loss per common share, basic	$ (0.30)	$ (1.58)	$ (0.65)	$ (2.80)
Net loss per common share, diluted	$ (0.30)	$ (1.58)	$ (0.65)	$ (2.80)
Weighted average number of common shares outstanding, basic	12,916,272	7,028,156	11,386,266	6,587,850
Weighted average number of common shares outstanding, diluted	12,916,272	7,028,156	11,386,266	6,587,850